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Abstract: It is unclear how the prevalence of people who believe the gluten-free diet (GFD) to be
generally healthy (“Lifestylers”) is impacting the overall rates of self-reported gluten sensitivity (GS).
We repeated a population survey from 2012 in order to examine how attitudes towards GS have
changed over time. Our survey (N = 1004) was administered in Sheffield (UK) in 2015, replicating the
2012 experiment. The questionnaire included a food frequency survey and assessed self-reported GS
as well as associated variables (prevalence, current diet, pre-existing conditions, etc.). The overall
rates of key variables and chi-squared analysis in comparison to the previous survey were as follows:
self-reported GS was 32.8% (previously 12.9%, p < 0.001), pre-existing coeliac disease (CD) was 1.2%
(previously 0.8%, p = 0.370), following a GFD was 3.7% (previously 3.7%, p = 0.997). Self-reported GS
was positively associated with some pre-existing conditions, including anxiety, depression, chronic
fatigue, headaches, and other food allergies/intolerances (including irritable bowel syndrome (IBS);
chi-squared analyses, all p < 0.001). Over a 3-year period, the fraction of people who self-reported
GS increased by over 250%. Despite this, arguably more meaningful indications of underlying
physiological GS remained comparable. This research suggests that the public perception of gluten is
causing a marked increase in the number of people who erroneously believe they are sensitive to it.
Keywords: gluten sensitivity; population survey; people who avoid gluten; lifestylers; coeliac disease
1. Introduction
Although studies repeatedly indicate that the prevalence of coeliac disease (CD) is approximately
0.5%–1% in the United Kingdom (UK) and American populations [1–3], the elimination and restriction
of gluten from diets has increased dramatically in recent years. The total value of the global gluten-free
food industry has grown from $1.7bn in 2011 to $3.5bn in 2016 and is forecast to reach $4.7bn in 2020 [4].
Non-coeliac gluten sensitivity (NCGS) [5] describes a physiological sensitivity to gluten in the absence
of CD or wheat allergy (WA), and this population undoubtedly contributes to the popularity of the
gluten-free diet (GFD) outside of CD patients. Although the precise nature of NCGS is the subject of
some debate, notable studies have shown findings which support gluten as being a causative agent in
this syndrome [6–9]. However, celebrity and athletic endorsements of the GFD have also cultivated
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an image that it is healthy for all people [10]. This is not supported by the scientific literature, which
continues to assert that gluten is safe to eat for individuals without any forms of gluten sensitivity
(GS) [11]. Encouraged by this perception of healthy eating, many people now eat gluten-free food as a
lifestyle choice. These are known as “Lifestylers”, “clean eaters”, “free from”, or sometimes “people
who avoid gluten”.
Scientific research assessing the prevalence and effects of this belief is lacking, although indications
may be inferred from other sources. International Google Trends data concerning the search term
“gluten free healthy” (accessed on 1May 2019) show that the search has steadily increased in popularity
from 2009, before peaking in 2014. It has remained very popular with an interest level in the third
quartile (when compared to the first quartile prior to 2009). This implies approximately five times
as much interest if the middle values of each quartile are compared (i.e., 12.5 vs. 62.5). Lifestylers
also appear to account for a substantial proportion of those engaged with a GFD. American market
research conducted in 2013 [12] and 2014 [13] found that 44% of people who buy gluten-free food do
it for reasons other than any kind of GS, and that 65% of people believed that a GFD was generally
healthier. A qualitative study performed in the UK assessing the attitudes of people with NCGS also
uncovered some responses which indicated a perception of gluten as being generally unhealthy [14],
which suggests that Lifestyler beliefs are also now directly influencing the self-reporting of GS.
Additional dilution of the NCGS population likely occurs due to the overlap of symptoms with
other food intolerances, such as irritable bowel syndrome (IBS) [15]. Indeed, it is thought that this is
one reason why some NCGS studies show negative results [16]. It would be expected that the high
level of Lifestyler interest in a GFD would further increase the possibility of people over-attributing
such similar symptoms to it, and in others may encourage a “nocebo” effect upon commencing a
GFD. As the self-reporting of symptoms due to gluten is the central diagnostic feature for NCGS, it is
important that the clinical and public perception of gluten remains balanced. The surge in gluten-free
popularity has also led to an opposing belief that it is a “fad” diet [17,18]. This can affect people with
CD/NCGS, who find that their condition is taken less seriously in contexts such as eating out at a
restaurant [19].
In 2012 we conducted a UK population-based questionnaire which found that while 12.9% of
respondents reported GS, those who were on a GFD only accounted for 3.7% [20]. As clinically
diagnosed NCGS often causes severe symptoms and thus provides strong motivation for patients
to adopt a GFD, such a disparity may be indicative of a Lifestyler demographic with a less notable
and/or specific presentation. We undertook a population-based survey to re-characterise the number of
people who self-report gluten sensitivity since that survey, and then investigate associated phenomena
such as amounts of dietary gluten consumed and the co-occurrence of other conditions.
2. Materials and Methods
2.1. Participants
Participants were recruited outside a large shopping centre in Sheffield, UK between September
and October 2015. This was the same as the main recruitment location from the previous survey
conducted by the group in 2012 [20] so that changes over the intervening 3 years could be comparably
assessed. The only criteria were that the subjects were aged 16 or older. There were 1004 people
recruited for the study that completed the questionnaire.
The population survey was supported by personal research funds of Prof. Sanders. The project
was discussed with Sheffield Teaching Hospitals Foundation Trust and the regional Research Ethics
Committee prior to commencement, and as the study was a public survey conducted entirely outside
of healthcare services, it was determined that formal ethical approval was not required. Regardless,
the project fell within the remit of a “blanket” ethical approval granted by the Yorkshire & Humber
(Sheffield) Research Ethics Committee, for research into CD, potential CD, and gluten sensitivity.
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The project was otherwise conducted in accordance with the principles outlined in the Declaration
of Helsinki.
2.2. Methods
The questionnaire was a modified version of the one previously administered in 2012 [20] (which
has also been implemented in other settings [21,22]). It was first used to assess dietary gluten via a
food frequency survey (adapted from others which have been validated in children [23,24]). It was
then used to collect demographic information and characterise whether the respondent had any of a
number of pre-existing medical conditions. Finally, the questionnaire was used to identify if the subject
self-reported a GS, and then interrogated associated variables, including specific symptoms (and their
course), if the subject has ever been assessed by a healthcare professional for GS (and if they received a
CD or WA diagnosis), and if they were on, or had ever tried a GFD. The questionnaire is available in
the Supplementary Material as Item S1.
2.3. Data Analysis
All analysiswas conducted in SPSS version 23. Key variableswere summarised so that a descriptive
comparison could be made to the accompanying study that was conducted 3 years previously. X2 tests
were used to separately analyse if the fraction of respondents who self-reported GS, adhered to a GFD,
or had CD were significantly different between these studies. The overall fraction of self-reported
GS/GFD adherence included those with diagnosed gluten-related disorders in order for these rates to
be wholly comparable between surveys.
Statistical analyses were then conducted to more closely examine the features of people who
self-reported a GS without having been diagnosed CD or WA (i.e., those who appear to have a NCGS).
The X2 analyses examined the relationship between NCGS and the occurrence of pre-existing medical
conditions. After a visual inspection of the histogram to confirm normality, themean daily consumption
of gluten (calculated from the food frequency questionnaire) was compared by a t-test between the
NCGS and non-GS groups.
3. Results
3.1. Overall Population Characteristics
The 1004 subjects that were recruited into the questionnaire had a mean age of 36.6 years (range =
16–86, SD = 17.2), and 59.2% were female. The overall mean amount of gluten consumed daily was
13.2 g (SD = 9.2). The rate of people reporting pre-existing gastrointestinal disorders was as follows:
stomach or bowel cancer = 0% (N = 0), gastroesophageal reflux disease (“reflux”) = 6.4% (N = 64),
irritable bowel disease = 0.3% (N = 3). IBS was reported as a pre-existing condition without any of
these diseases (or CD; characterised later) in 4.4% of respondents (N = 44) and was reported with an
overall rate of 5.2%.
3.2. Self-Reported Gluten Sensitivity
The rate of self-reported GSwas 32.8% (N = 329). This sub-group had amean age of 37.7 (SD= 16.0)
and was 66.4% female. The most reported symptom was bloating (72.0%), followed by abdominal pain
and discomfort (41.0%), lack of energy (31.0%), flatulence (24.6%), and constipation (20.1%). Diarrhoea,
headaches, acid reflux, urgency to open bowels, and belching were all reported at rates between
10%–20% (inclusive). Foggymind, joint pains, feelings of incomplete bowel emptying, nausea/vomiting,
and skin rashes were reported between 5%–10%, while anaemia, co-ordination problems, mental
confusion, numbness/tingling, and fainting were all reported at <5%. This is visualised in Figure 1.
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Figure 1. Pie charts showing the distribution of intestinal (left) and extra-intestinal (right) symptoms
amongst respondents who self-reported gluten sensitivity.
Of the overall self-reported GS subgroup (i.e., including those with diagnosed gluten-related
disorders), 25.5% had previously tried a GFD, of whom 75.0% said this helped with their symptoms
(the remaining 25.0% either answered that the diet did not help or that they were not sure). The total
proportion of people who self-reported GS, and who were presently on a GFD at the time of the
questionnaire was 11.2% (N = 37, meaning the overall rate of people on a GFD within the whole
population was 3.7%). In people who self-reported a GS, 14.0% said they had a reaction every time
they ate gluten, while 19.1% had seen a healthcare professional at some point about their symptoms,
leading to 3.6% of them to receive a CD diagnosis (N = 12) and 1.5% of them to receive a WA diagnosis
(N = 5). The overall rate of CD within the whole population was therefore 1.2%, while the overall rate
of self-reported GS without CD or WA (i.e., NCGS) was 31.1%. All respondents who reported CD
indicated they had been diagnosed via formal clinical testing that included coeliac blood tests in all
12 cases, and also an endoscopy in 11 out of 12 cases (also reported: skin prick allergy test in N = 3,
colonoscopy in N = 2, biopsy in N = 1, and lactose intolerance test in N = 1).
Table 1 gives an overview of the key variables contained in both the 2012 and 2015 questionnaires,
for a descriptive comparison [20]. To summarise, we had previously reported an overall rate of
self-reported GS (including diagnosed gluten-related disorders) at 12.9% (presently 32.8%), with a
clinical diagnosis of CD at 0.8% (presently 1.2%), and the total number of people on a GFD at 3.7%
(presently also 3.7%). The chi-squared analysis showed the difference in GS reporting rates to be highly
significant (p < 0.001), while GFD (p = 0.997) and CD (p = 0.370) were non-significant.
Further analyses focused on comparisons between those with NCGS (i.e., self-reported GSwithout
CD or WA) and respondents who did not report any form of GS. Within the current questionnaire,
daily gluten intake of the NCGS group (mean = 11.3 g, SD = 8.2) was significantly lower than in
people without self-reported GS (mean = 14.4 g, SD = 9.4, independent t-test p < 0.001). X2 analyses
showed that the NCGS group more often reported pre-existing disorders of anxiety (NCGS = 22.4%,
non-GS = 8.0%, p < 0.001), depression (NCGS = 14.7%, non-GS = 4.4%, p < 0.001), chronic fatigue
(NCGS = 3.5%, non-GS = 0.6%, p < 0.001), myalgic encephalomyelitis (NCGS = 10.3%, non-GS = 3.4%,
p < 0.001), chronic headaches (NCGS = 9.0%, non-GS = 2.7%, p < 0.001), egg allergy (NCGS = 3.2%,
non-GS = 0.3%, p < 0.001), dairy intolerance (NCGS = 5.1%, non-GS = 0.7%, p < 0.001), acid reflux
(NCGS = 11.2%, non-GS = 4.1%, p < 0.001), and IBS (NCGS = 9.0%, non-GS = 3.3%, p < 0.001). These
findings all survived the Bonferroni correction. Provisionally significant results of the same direction
(i.e., p < 0.05, where NCGS respondents more often reported the condition), but which did not survive
this correction, were also reported for thyroid disease and fibromyalgia. Note that for comparison
with the previous survey (which also investigated the occurrence of pre-existing conditions, but in the
overall self-reporting GS group), these findings remain significant if including those with CD/WA (see
Table 1 for comparisons).
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Table 1. Comparison of the key variables between the current study (conducted in 2015) and the 2012
questionnaire it replicates. The p-values indicate X2 analyses to compare the rate of self-reported gluten
sensitivity, coeliac disease (CD), and an adherence to a gluten-free diet (GFD).
Variable
As Reported in 2012
(Overall N = 1002)
As Reported in The Current
Study (Measured in 2015,
Overall N = 1004)
Chi-Squared p Value
(Where Conducted)
Prevalence of self-reported
gluten sensitivity
12.9%
(N = 129)
32.8%
(N = 329)
p < 0.001
Mean age (years) of people with
self-reported gluten sensitivity
39.5 ± 17.7 37.7 ± 16.0 -
% Female within people with
self-reported gluten sensitivity
79% 66% -
Overall prevalence of coeliac
disease diagnosis
0.8%
(N = 8)
1.2%
(N = 12)
p = 0.370
Overall prevalence of people
adhering to a GFD
3.7%
(N = 37)
3.7%
(N = 37)
p = 0.997
Pre-existing conditions which
gluten-sensitive individuals are
more likely to have
Anxiety, Depression, Chronic
fatigue syndrome, Food
allergies/intolerances, IBS
(rates not reported)
Anxiety (22.4%), Depression
(14.7%), Chronic fatigue
syndrome (3.5%), Myalgic
encephalomyelitis (10.3%),
Chronic headaches (9.0%), Acid
reflux (11.2%), Food
allergies/intolerances/IBS
(3.2%–9.0%)
-
4. Discussion
This population survey indicates that in 2015, nearly a third of the general UK population
perceived that they had symptoms related to the ingestion of gluten. This is in contrast to a comparable
survey conducted in 2012, which found a much lower prevalence, suggesting that there was a dramatic
increase in the number of people in the UKwho believe they have GS, despite there being no underlying
change in the number of individuals on a GFD.
Patients who self-report symptoms related to gluten must have CD excluded, although the rate
of self-reported GS presented here is far higher than any estimate of CD prevalence, even when
taking undiagnosed cases into account [1]. Physiological GS may also exist as NCGS. NCGS is
often the subject of debate, although notably a meta-analysis of randomised placebo-controlled trials
investigating symptomatic response to gluten did indicate an overall positive effect when included
studies were limited to those which followed consensus criteria for the definition and investigation
of the syndrome [6] (the “Salerno” criteria [5]). Additionally, other literature has demonstrated
physiological changes in NCGS populations when compared to controls or CD patients, indicating that
gluten may cause an activation of the innate immune system [9]. The sum of this research suggests that
sensitivity to gluten does exist outside of CD and WA. However, as effective clinical testing for NCGS
remains unavailable, the self-reporting of gluten-related symptoms is the most pertinent diagnostic
criteria. This emphasises the importance of a balance in the public’s understanding of the reactions
that can be caused by gluten.
NCGS is thought to affect between 0.5%–13% of the population [25], meaning the overall rate
of self-reported GS found in the present study is remarkably high even when taking this population
into account. There are a number of reasons why an overestimation of self-reported GS may be
occurring. The overlap between NCGS and IBS is close, and it has been proposed that many individuals
experiencing IBS [15] or other similar intolerances [16] may erroneously confuse their condition as
being gluten-driven. However, the rate of people with underlying food sensitivities is unlikely to
have changed between 2012–2015, so other factors must be considered. Scientific studies specifically
investigating the impact of “Lifestyler” beliefs within the NCGS population are lacking, but these
attitudes likely hold a strong influence. One qualitative study assessing the beliefs of an NCGS group
detected some Lifestyler-type responses, including statements such as “Grains and sugar are slowly
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killing us all!!” [14]. A rise in such beliefs may additionally encourage the self-misdiagnosis of IBS (by
making gluten a more prominent consideration), and also lead to “nocebo” effects after eating gluten.
Our 2012 survey was conducted using a comparable population-based questionnaire where we
found that 12.8% of people self-reported GS [20]. The contemporary survey’s finding of 32.7% therefore
represents a highly significant increase of over 250%. On the other hand, in the present study the
number of people who had CD (1.1%) or were on a GFD (3.8%) were not different from this previous
experiment (0.8% and 3.7%, respectively). Overall IBS prevalence (without other gastrointestinal
conditions) was also comparable, with rates of 4.4% and 6% in the present/previous study (for reference
these rates are similar to the lower end of the UK IBS prevalence estimates—6.1% [26]). Therefore,
despite a marked rise in self-reported GS, behaviours and diagnoses which would meaningfully
support that this increase has a physiological basis did not change. Of relevance to this, it should also
be noted that this disparity between the rate of people who self-report GS and the fraction of those
who adhere to a GFD is far greater here than has been found in similar studies in Mexico [27] (overall
GS; 11.9%, GFD; 3.7%) and Colombia [28] (overall GS; 7.9%, GFD; 5.9%). Our finding that 25% of GS
subjects who had tried a GFD did not report that it helped further shows that for many people who
label themselves as gluten-sensitive, the perceived connection between gluten and the symptoms it
causes does not need to be clear.
Overall our results suggest that the reasons for the increase in self-reported GS are likely driven
by factors other than clear physiological GS, supporting the hypothesis that the misplaced belief that
gluten is generally unhealthy has influenced this. Our findings scientifically demonstrate that the
number of people who self-report GS is rising, and suggest that the increase in Lifestyler beliefs as
evidenced by Google Trends between 2009–2014 (detailed in the Introduction) is leading to this.
A number of results from the questionnaire did however draw some links between NCGS (i.e.,
self-reported GS without diagnosed CD or WA) and clinical outcomes. People with NCGS overall
consumed less daily gluten, implying some level of restriction, and more often reported a range of
pre-existing conditions including depression, anxiety, headaches, fatigue, reflux, and IBS. These show
parity with symptoms and conditions associated with CD [29,30]. Notably however, a study which
investigated Lifestylers specifically reported an opposing finding by showing depression to occur at a
lower rate in this group [31]. It is likely that our results stem from those within the NCGS group who
do have clinical conditions. These may either be people with correctly identified NCGS, or people with
other related disorders such as IBS who are mistaking their symptoms for GS. There is no reason to
suspect that the prevalence of people with these physiological susceptibilities has increased since the
2012 questionnaire, meaning that the number of people within the total self-reported GS population
who do have disorders is probably becoming more diluted.
There are some limitations to this study. Some potentially valuable details were not collected in the
survey. Further work would benefit from directly assessing information, such as whether respondents
understand what gluten is, if they believe it is generally unhealthy to eat, or their given reason for
believing they are GS (aside from attributing some symptoms to it; this would be particularly valuable
in the sub-population who do not claim to benefit from a GFD).
In conclusion, this survey provides scientific evidence that the gluten-free “fad” has now led to a
sharp increase in the number of people who believe they have GS. However, current clinical opinion
supports that gluten is fine for the people without a demonstrable sensitivity to it. As the GFD has
been suggested as an overall sub-optimal diet [32], if anything there is a possible need for dissuading
the notion that gluten is generally unhealthy. Further, as the prevalence of the diet has also encouraged
scepticism of it in a number of people [17], there is a risk that such continued interest will cause patients
with physiological GS (CD, NCGS, etc.) to be treated less compassionately in pertinent settings such as
restaurants [15]. This study therefore provides some important impetus in grounding the public and
clinical perspectives on the topic of gluten sensitivity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/6/1276/s1,
Item S1: Gluten Food Frequency Questionnaire.
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